Bipolar disorder is a common and severe condition, and has a clinical outcome that is frequently sub-optimal. Only a small number of therapeutic options are currently available for the disorder. A growing range of novel therapeutic options for the treatment of bipolar disorder are under investigation. These include the anticonvulsants, atypical antipsychotics and options such as the omega-3 fatty acids and transcranial magnetic stimulation. Of the anticonvulsants, lamotrigine is currently the agent for which the greatest amount of controlled clinical data is accumulating, particularly in the depressed and rapid cycling phases of the illness. Olanzapine is currently the atypical antipsychotic with the largest body of evidence in mania, although data is emerging on other atypical antipsychotics including risperidone and ziprasidone. Data regarding the atypical agents in other phases of the illness are awaited. The options available for this difficult to treat condition is increasing with the new range of agents.
双相情感障碍是一种常见且严重的疾病,其临床结果通常不尽如人意。目前针对该疾病的治疗选择较少。越来越多的新型治疗选项正在研究中,包括抗癫痫药、非典型
抗精神病药,以及如omega-3
脂肪酸和经颅磁刺激等选项。在抗癫痫药中,
拉莫三嗪目前是积累了最多对照临床数据的药物,特别是在抑郁和快速循环发作阶段。
奥氮平目前是针对狂躁症有最多证据的非典型
抗精神病药物,尽管关于其他非典型
抗精神病药物如
利培酮和
齐拉西酮的数据也在逐渐出现。针对该疾病其他阶段非典型药物的数据尚待发布。随着新药物的出现,治疗这一难治性疾病的选择正在增加。